Evidence map›Paper›PMID 21480973›Full record

GuidelineDiabetic medicine : a journal of the British Diabetic Association2011

Bariatric surgery: an IDF statement for obese Type 2 diabetes.

J B Dixon, P Zimmet, K G Alberti, F Rubino, International Diabetes Federation Taskforce on Epidemiology and Prevention

2 registry-linked trialsOpen access · bronzeAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Diabetic medicine : a journal of the British Diabetic Association, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 171 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
171citing papers in PubMed, 11 pooled it
59.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02041234 phase4completedstarted 2014, after this paper: background citation

Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes vs Best Medical Treatment

Ran2014Enrolled40Registered outcomes16Posted comparisons0ConditionsType II Diabetes in Subjects BMI 27 to 32ArmsDPP-4 Inhibitors, Incretin analogues, Roux-en-Y Gastric Bypass (RYGB), SGLT2 inhibitors, Xenical
PMID 7677463PMID 22449319PMID 22723580PMID 17715408PMID 19272486PMID 19370590PMID 22449317other papers from this trial
Open the trial in the graph
NCT02459561 naunknown statusnot on this mapstarted 2015, after this paper: background citation

A Randomised Controlled Trial of a Duodenal Sleeve Bypass Device (EndoBarrier)Compared With Standard Medical Therapy for the Management of Obese Subjects With Type 2 Diabetes

TypeinterventionalSponsorImperial College LondonRan2015 to 2019Enrolled170ConditionsOverweight and Obesity, DiabetesArmsEndoBarrier TM Gastrointestinal Liner, Best Medical Care
3 · Its place in the literature

Who cites it

171 citing papers in PubMed, 11 syntheses or guidelines pooled it, 497 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Guideline
  11. Guideline
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

111 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

J B DixonBaker IDI Heart and Diabetes Institute, 99 Commercial Road, Melbourne, Victoria, Australia.
P Zimmet
K G Alberti
F Rubino
International Diabetes Federation Taskforce on Epidemiology and Prevention
Baker Heart and Diabetes Institute · AUCornell University · USImperial College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The International Diabetes Federation Taskforce on Epidemiology and Prevention of Diabetes convened a consensus working group of diabetologists, endocrinologists, surgeons and public health experts to review the appropriate role of surgery and other gastrointestinal interventions in the treatment and prevention of Type 2 diabetes. The specific goals were: to develop practical recommendations for clinicians on patient selection; to identify barriers to surgical access and suggest interventions for health policy changes that ensure equitable access to surgery when indicated; and to identify priorities for research. Bariatric surgery can significantly improve glycaemic control in severely obese patients with Type 2 diabetes. It is an effective, safe and cost-effective therapy for obese Type 2 diabetes. Surgery can be considered an appropriate treatment for people with Type 2 diabetes and obesity not achieving recommended treatment targets with medical therapies, especially in the presence of other major co-morbidities. The procedures must be performed within accepted guidelines and require appropriate multidisciplinary assessment for the procedure, comprehensive patient education and ongoing care, as well as safe and standardized surgical procedures. National guidelines for bariatric surgery need to be developed for people with Type 2 diabetes and a BMI of 35 kg/m(2) or more.

Indexed as

Bariatric SurgeryCost-Benefit AnalysisDiabetes Mellitus, Type 2FemaleHumansMaleObesity, MorbidPatient Selection

Identifiers

PMID21480973
PMCPMC3123702
OpenAlexW2170005843

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.